RIXUBIS [COAGULATION FACTOR IX (RECOMBINANT)] For the treatment of adults and children with Hemophilia B (factor IX deficiency)
Striving for ZERO BLEEDS icon
39%

of patients
< 12 Years
of Age

43%

of patients
≥ 12 Years
of Age

experienced zero bleeds during 6 months of RIXUBIS prophylactic treatment*12

*Prophylaxis efficacy of RIXUBIS was studied in 56 previously treated patients between 12 and 65 years of age and 23 previously treated patients between 1.8 and 11.8 years of age with severe or moderately severe hemophilia B for a mean treatment duration of 6 months.12

news icon

News and Updates

SIGN UP
FREE price tag icon

Try RIXUBIS for Free Today

GET STARTED
icon of wallet and credit card

Need help paying for RIXUBIS?

LEARN MORE
icon of silhouetted people

Meet your local representative

CONNECT
43%
of patients experienced zero bleeds during 6 months of RIXUBIS prophylactic treatment*1
  • *Prophylaxis efficacy of RIXUBIS was studied in 56 previously treated patients between 12 and 65 years of age with severe or moderately severe hemophilia B for a mean treatment duration of 6 months.1